CONTENTS
Assistant Editor
Special Assignments
julia aalbers
Tel: 021 976 4378
Fax: 086 610 3395
e-mail:
Production Editor
SHAUNA GERMISHUIZEN
Tel: 021 785 7178
Fax: 086 628 1197
e-mail:
Editorial Assistant &
Circulation
ELSABÉ BURMEISTER
Tel: 021 976 8129
e-mail:
Production
Co-ordinator
WENDY WEGENER
Tel: (021) 976-4378
e-mail:
GAUTENG CONTRIBUTOR
PETER WAGENAAR
Cell 082 413 9954
e-mail :
Editorial BOARD
The
Cardiovascular Journal of Africa
,
incorporating the
Cardiovascular
Journal of South Africa
, is published six
times a year, the deemed publication
date being the seventh day of the
second designated month,
i.e. 7 February, 7 April, 7 June, 7
August and 7 October.
Copyright:
Clinics Cardive Publishing, Pty, Ltd.
Layout:
Martingraphix
Printer:
Durbanville Commercial Printers
All submissions to CVJA are to be
made online via
Electronic submission by means of an
e-mail attachment may be considered
under exceptional circumstances.
Postal address: PO Box 1013,
Durbanville, 7551
Tel/Fax: 021 976 8129
Int.: +27 21 976 8129
e-mail:
Electronic abstracts available on
Pubmed
Audited circulation
Full text articles available on:
or via
co.za; for access codes contact
User ID: cvja8
Password: cvja8
Subscriptions for six issues:
South Africa: R300 (excl VAT)
Other African countries: $30
Overseas: Institutions: R845 ($82)
Individuals: R1 080 ($105)
The views and opinions expressed
in the articles and reviews published
are those of the authors and do not
necessarily reflect those of the editors
of the Journal or its sponsors. In all
clinical instances, medical practitioners
are referred to the product insert
documentation as approved by the
relevant control authorities.
VOL 21, NO 6. NOVEMBER / DECEMBER 2010
Review Article
334 Contemporary insights into the pathogenesis, diagnosis and therapy of pulmonary
arterial hypertension
MR Essop
Opinions in Hypertension Management
338 ARBs and risk of cancer: international and South African expert comment
C Lombard • A Nosworthy • J Aalbers
Drug Trends
341 FDA committee unanimously recommends approval of dabigatran etexilate for stroke
prevention in atrial fibrillation
J Aalbers • A Bryer • E Klug
Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
J Aalbers
Development of new anticoagulant highly honoured: Bayer’s Xarelto
®
recognised with
2010 international Prix Galien award
Myocardial salvage after myocardial infarction depends on early therapy
J Aalbers
Your Life and Your Heart
348 Vitamin D is a prognostic marker in heart failure
J Aalbers
It's the
shell that
makes
safer.
R
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
